What is ReGelTec?
ReGelTec, Inc. is a clinical-stage medical device company dedicated to advancing treatments for chronic low back pain stemming from degenerative disc disease. The company's core innovation, HYDRAFIL, is a next-generation injectable hydrogel designed for minimally invasive procedures. This proprietary technology integrates with the existing intervertebral disc, aiming to preserve spinal motion while substantially alleviating pain and disability. ReGelTec's target market includes healthcare providers and patients afflicted by degenerative disc disease, with the overarching goal of enhancing their quality of life through advanced spinal implant solutions. The company has garnered recognition as a breakthrough Medtech startup and has successfully obtained CE Mark approval for its HYDRAFIL System.
How much funding has ReGelTec raised?
ReGelTec has raised a total of $3.8M across 1 funding round:
Series A
$3.8M
Series A (2020): $3.8M with participation from Abell Foundation
Key Investors in ReGelTec
Abell Foundation
The Abell Foundation is a philanthropic organization focused on enhancing the quality of life in Maryland, with a specific emphasis on supporting initiatives in Baltimore City and opening opportunities for the disenfranchised.
What's next for ReGelTec?
The substantial enterprise-level funding and recent strategic investment position ReGelTec for accelerated growth and market penetration. With CE Mark approval secured for its HYDRAFIL System, the company is poised to scale its operations, expand its commercial reach, and further its clinical development pipeline. This capital infusion will likely support enhanced manufacturing capabilities, broader clinical trials, and strategic partnerships to bring its innovative hydrogel technology to a wider patient population suffering from degenerative disc disease.
See full ReGelTec company page
